RxDoctor Payments DataLook up a doctor →

Steven Siwek, MD

Interventional Pain Medicine · Phoenix, AZNPI 1932204435

Payments from drug & device makers

$161,306in general payments, 2019–2025

Across 639 payments — averaging $252.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Pfizer$105K
  • Orthofix Medical, Inc.$38K
  • Abbott$7K
  • Impactortho, Inc.$2K
  • Boston Scientific$2K
  • Vertos Medical, Inc.$1K
  • plus $7K from 39 others

What the payments were for

  • Travel & lodging$6281%
  • Food & beverage$15,91028%
  • Education$2,1744%
  • Entertainment$120%
  • Other$37,98567%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$161,306 in reported general payments places this provider in the 85th percentile of 64 interventional pain medicine providers in Arizona.

See all interventional pain medicine providers in Arizona

Medicare billing

Part B allowed, 2024
$221,397
Medicare patients
272
Services billed
2,811

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate23$8,745
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen244$7,451
MovantikNaloxegol Oxalate11$4,649
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen173$4,418
Buprenorphine16$3,377
Gabapentin174$2,525
Pregabalin80$2,439
Oxycodone Hcl104$1,931
Morphine Sulfate ErMorphine Sulfate81$1,746
Tramadol Hcl134$1,215
Diclofenac Sodium30$990
Cyclobenzaprine Hcl70$979
Tizanidine Hcl60$744
Baclofen42$693
Celecoxib25$521

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$123$8,74523 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 64 interventional pain medicine providers in Arizona.

Other interventional pain medicine in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →